This study is a critical analysis of the association between selective serotonin reuptake inhibitors (SSRIs) exposure during pregnancy and autism spectrum disorder (ASD) risk in children. Electronic databases were searched for observational studies published from January 1946 to June 2014 related to the association between SSRI exposure during pregnancy and ASD in children. Studies relevant to the association between SSRI exposure during pregnancy and ASD in children were extracted and compiled for meta-analysis evaluation. Ninety-five citations were identified and seven observational studies were included. Four case-control studies were eligible for the meta-analysis and two cohort studies were narratively reviewed. The pooled crude and adjusted odds ratios of the case-control studies were 2.13 (95% CI 1.66-2.73) and 1.81 (95% CI 1.47-2.24) respectively. Low heterogeneity was observed between studies. The two population-based cohort studies; utilized the same Denmark data set, have conflicting results. The findings of this meta-analysis and narrative review support an increased risk of ASD in children of mothers exposed to SSRIs during pregnancy; however, the causality remains to be confirmed.
Main Text: Introduction
Untreated maternal depression has been associated with poor health outcomes for both mothers and children (Sontag-Padilla et al. 2013) . Antidepressants are therefore indicated for pregnant women if the benefits outweigh the risk (National Institute for Health and Clinical Excellence 2007; Joint Formulary Committee 2014) . Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed anti-depressant classes. Substantial placental transfer occurs with SSRIs (Rampono et al. 2009 ) and may cause unwanted effects to the unborn child. Currently, meta-analysis results demonstrate that SSRI exposure during pregnancy is associated with preterm birth and low birth rate (Huang et al. 2014) , congenital malformation (Myles et al. 2013) , and persistent pulmonary hypertension (Grigoriadis et al. 2014) . The use of SSRIs in pregnant women is a complex decision that requires weighing the effectiveness of treating depressive symptoms while considering potential adverse events in mother and child.
Recent studies have indicated a possible association between the use of SSRIs in pregnancy and the risk of autism spectrum disorder (ASD) in children (Croen et al. 2011; Eriksson et al. 2012; Gidaya et al. 2014; Harrington et al. 2014; Hviid et al. 2013; Rai et al. 2013; Sorensen et al. 2013 ).
SSRIs are able to cross not only the blood-brain barrier for intended pharmacological actions but also the placental barrier for possible unintended consequences (Kendall-Tackett and Hale 2010) . This is evidenced by the high SSRI cord/maternal distribution ratio, i.e., 0.70-0.86 (Rampono et al., 2009 ).
Animal studies demonstrate that transient usage of fluoxetine during early development produces abnormal emotional behaviors in adult mice, suggesting the role of serotonin transporter modulation during development of brain systems involved in emotional and stress related responses (Ansorge et al. 2004 ). Pharmacokinetic and pharmacodynamic data, albeit weak and indirect in nature, suggest a plausible biological mechanism between in-utero exposure of SSRIs and ASD in children. However, in the scientific literature, evidence of this association contradicted several epidemiological studies supporting a positive association (Croen et al. 2011; Eriksson et al. 2012; Gidaya et al. 2014; Sorensen et al. 2013 ) whilst others indicated no association (Harrington et al. 2014; Hviid et al. 2013; Rai et al. 2013 ). Given conflicting results from studies, it is difficult to reach a consensus as to whether there is a link between the use of SSRIs in pregnancy and ASD in children.
ASD affects 1 in 88 children in the United States (US) and prevalence is approximately 1 to 1.2% in the United Kingdom (UK) (Baird et al. 2006; Baron-Cohen et al. 2009 ). Due to ASD's early onset, their lifelong persistence and associated pervasive impairment (Simonoff et al. 2008) , there is significant impact on social outcomes, education and health of patients and their families (Bolton et al. 1998; Buescher et al. 2014 ). In the US and UK, the cost of supporting an ASD individual with intellectual disability throughout their lifetime is estimated to be US$2.2-2.4 million and US$1.4 million for an ASD individual without intellectual disability (Buescher et al. 2014) . Additionally, there is a high prevalence of mental health conditions in individuals with ASD, including attention deficit hyperactivity disorder, global and specific learning disabilities, emotional disorders, anxiety and depressive disorders, and chronic tic disorder (Bradley and Bolton 2006; Green et al. 2005; Simonoff et al. 2008) . Understanding the risk factors for the development of ASD is an important public health issue.
In view of the above issues, we undertook a systematic review and meta-analysis of published observational studies to evaluate whether SSRI exposure during pregnancy increases the risk of ASD in children.
Method
A systematic literature search was conducted using the search terms (SSRI OR Serotonin uptake inhibitor OR antidepressant) AND pregnancy AND (autism OR autistic OR pervasive developmental disorder OR Asperger syndrome OR Asperger's syndrome OR ASD). PubMed, EMBASE, PsycINFO and the Cochrane Review databases were searched up to 25 June 2014. English titles and abstracts were screened and full texts of relevant articles were retrieved for further review to identify relevant studies. A hand-search of selected articles was conducted to further identify pertinent studies. This study was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) for the flow chart and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) to ensure clear and comprehensive reporting.
Inclusion and exclusion criteria
Observational studies, including cohort and case-control study designs, which investigated the association between SSRI use and ASD were included. Case reports and animal studies were excluded.
Quality assessment
As recommended by the Cochrane Collaboration (Higgins and Green 2011) , the methodological quality of the included studies were assessed using the Newcastle-Ottawa Scale (NOS) (Wells et al. 2000) . Two authors (HT and LW) independently reviewed and scored each study. Separate NOS criteria were used for case control and cohort studies. A maximum of nine stars could be allocated for the following categories: selection, comparability and outcome/exposure. The total score was obtained by adding the number of stars in the sub-categories where a higher score indicated better quality.
Data extraction
Data from the included studies were extracted using a standardized data collection form.
These included study duration and design, data source, covariates, exposure groups, and sample size.
Authors HT and LW independently extracted data and completed the characteristics form that was subsequently cross-matched to ensure consistency and accuracy.
Outcome parameters such as relative risk (RR), crude odds ratio (OR), adjusted OR and the corresponding 95% confidence intervals (CI) were extracted and included in the meta-analysis if appropriate.
The primary outcome of interest was the risk or odds of developing ASD following exposure to SSRIs, either at preconception, or during pregnancy.
Statistical analysis
To estimate the association between the use of SSRIs during pregnancy and ASD in children, the results of the included studies were combined using DerSimonian and Laird's random-effects model (DerSimonian and Laird 1986) to account for heterogeneity among studies. The MantelHaenszel fixed-effect model was used to validate the results and control for overweighting of the included small studies. All formulations of SSRIs were included. Analysis was performed on both the crude and adjusted estimates from the studies. The pooled estimates with 95% CI were calculated.
Sensitivity analysis was performed to assess the robustness of the results. This was conducted by substituting the findings of Rai et al. (2013) with those of Eriksson et al. (2012) as the subjects in these two studies came from the same data source.
As the studies included in the analysis were carried out in different settings, we examined the extent of heterogeneity among studies with the Cochran Q test (Higgins and Green 2011) , where a cutoff p-value of 0.1 was considered significant for heterogeneity. Higgin's I 2 -statistic (Higgins and Green 2011) was reported for each figure.
The background incidence rate of ASD was calculated by dividing the total number of ASD cases by the total number of people at risk in the respective data source. The corresponding 95%
confidence intervals were obtained using the Poisson method.
All probability values (two tailed) with a p-value of 0.05 were considered statistically significant. All analyses were conducted using Review Seventy-one records remained after the removal of duplicates. Titles and abstracts were screened and full texts of relevant articles were retrieved for further review with 64 studies meeting the exclusion criteria. Seven observational studies (Croen et al. 2011; Eriksson et al. 2012; Gidaya et al. 2014; Harrington et al. 2014; Hviid et al. 2013; Rai et al. 2013; Sorensen et al. 2013 ) were found to be relevant to the research question ( Figure 1 ). All the studies used healthcare databases in their analyses.
Disease codes such as the International Classification of Diseases, Ninth and Tenth Revision (ICD-9
and ICD-10) were used to identify cases, except for the study of Harrington et al., which used the Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule (ADOS) ( Table 1) . Included studies were of adequate quality with respect to study design, obtaining more than seven out of nine stars from the NOS quality assessment (Table 2 ).
Four case-control studies (Croen et al. 2011; Gidaya et al. 2014; Harrington et al. 2014; Rai et al. 2013) were eligible for the main meta-analysis, representing a total of 79,221 patients and controls. Rai et al. (2013) and Eriksson et al. (2012) used the same database; therefore Eriksson et al. was substituted for Rai et al. in a sensitivity analysis. Two cohort studies (Hviid et al. 2013; Sorensen et al. 2013 ) that used the same data source were narratively reviewed separately.
Meta-analysis
Four case-control studies (Croen et al. 2011; Gidaya et al. 2014; Harrington et al. 2014; Rai et al. 2013) were meta-analyzed. Two were from US (Croen et al. 2011; Harrington et al. 2014 ) and the others were from Denmark (Gidaya et al. 2014) and Sweden (Rai et al. 2013 ) ( Table 1 ). The commencing years of the studies ranged from 1995 (Croen et al. 2011 ) to 2010 (Harrington et al. 2014 ). In all case-control studies, children without an ASD diagnosis were the controls and samples were randomly taken from the corresponding databases (Croen et al. 2011; Gidaya et al. 2014; Harrington et al. 2014; Rai et al. 2013; Eriksson et al. 2012) . The use of SSRIs during pregnancy was significantly associated with an increased risk of ASD in children (pooled crude OR=2.13; 95% CI 1.66 to 2.73). No heterogeneity was found between studies (Q-statistics=0.5, p=0.92; I 2 =0%) and thus, there was no difference between the random and fixed-effects model (Figure 2) . The results remained similar and significant using the adjusted OR from each study (pooled adjusted OR=1.81; 95% CI 1.47 to 2.24) (Figure 3 ).
Sensitivity analysis by replacing Rai et al. (2013) with Eriksson et al. (2012) showed similar results (pooled crude OR=2.37; 95% CI 1.83 to 3.05) (Figure 4 ). However, low heterogeneity was observed (Q-statistics=3.97, p=0.26; I 2 =24%) and a slightly different estimate was found from the random-effects model (pooled crude OR=2.42; 95% CI 1.74 to 3.37) ( Figure 5 ).
Narrative review
Two cohort studies were included in this review. Both studies were conducted in Denmark using the Danish Civil Registration System, Danish National Prescription Registry and Danish Psychiatric Central Register as data sources (Hviid et al. 2013; Sorensen et al. 2013 Sorensen et al. (2013) found a significant association between the use of SSRIs during pregnancy and the risk of ASD in children (adjusted hazard ratio=1.6; 95% CI 1.3 to 2.0).
The background incidence rate of ASD was obtained from four studies (Gidaya et al. 2014; Hviid et al. 2013; Rai et al. 2013; Sorensen et al. 2013 ). The rate ranged from 5.91 to 8.48 per 1,000
patients. Significant differences between the incidence rates were observed ( Figure 6 ). As three out of four incidence rates were from the same data source, a pooled estimate was not compiled.
Discussion
To our knowledge, this is the first systematic review and meta-analysis of SSRI use in pregnancy and risk of ASD in children. Based on the results from the meta-analyses of the case control studies and review of cohort studies, SSRI exposure during pregnancy appears to be associated with the risk of ASD in children.
Three out of four published case-control studies reported significantly positive association between SSRI exposure during pregnancy and ASD in children (Croen et al. 2011; Gidaya et al. 2014; Rai et al. 2013 ). Although Harrington et al. (2014) reported non-significant results for the total sample, a statistically significant result was demonstrated when only males were considered. Additionally, since the sample size in Harrington et al. (2014) was the smallest of the studies (n=812), the statistically non-significant finding may be due to insufficient statistical power.
The pooled results in our meta-analysis of the four case-control studies (Croen et al. 2011; Gidaya et al. 2014; Harrington et al. 2014; Rai et al. 2013) gives an adjusted odds ratio of 1.81 (95% CI 1.47-2.24) with low heterogeneity among the studies (I 2 = 0.00). The identified studies were conducted in several countries (United States, Sweden and Denmark) using different data sources. However, they yielded similar results for risk (adjusted OR between 1.55 and 2.2). This lends further support to an association between SSRI exposure during pregnancy and ASD in children.
The two population-based cohort studies which utilized the same Danish dataset had slightly different results (Hviid et al. 2013; Sorensen et al. 2013 Although the results indicate an increased risk of ASD in children exposed to SSRIs during pregnancy, we cannot exclude any potential confounding effect on ASD detection in the studies.
Pregnant women with SSRI exposure are likely to have a greater frequency of medical consultations during and after pregnancy compared to non-exposed women (Sontag-Padilla et al. 2013) . In turn, their children may have more frequent medical encounters compared to other children, which could lead to a higher rate of ASD detection. As a result, we cannot exclude the possibility that the positive association is due to better detection of ASD in these children. If an increased risk were solely due to better detection, we would also expect an increased risk of ASD in children of mothers on other antidepressants during pregnancy. Both Croen et al. (2011) and Sorensen et al. (2013) provided evidence that this is not the case. Neither identified a significant association between the use of other antidepressants (tricyclics, dual-action antidepressants and serotonin-norepinephrine reuptake inhibitors) during pregnancy and the risk of ASD in children (Croen et al. 2011; Sorensen et al. 2013 ).
Both studies used medical databases as their data source with a reasonable sample size (1,805 in Croen et al and 648,097 in Sorensen et al). Their results do not support the idea that the risk of ASD in children will be higher due to greater detection.
The incidence rate of ASD in four studies were also estimated (Gidaya et al. 2014; Hviid et al. 2013; Rai et al. 2013; Sorensen et al. 2013 ) and Hviid et al. was found to have a lower rate (5.91 in 1,000 patients) despite the same data source as in studies by Sorensen et al. (2013) and Gidaya et al. (2014) . Variation in Hviid et al.'s (2013) exclusion criteria which excluded children with a number of genetic conditions, may have contributed to the difference in ASD incidence rate (Table 1) .
Studies investigating the association between SSRI in pregnancy and the risk of ASD in children in the literature are scant, possibly due to difficulties conducting studies in this area. As interventional studies would not be ethical in this clinical setting, observational studies appear to be more appropriate for investigating this association. However, obtaining a large sample size from a nondatabase study is challenging, with long follow-up time in the cohort setting and recall bias in the casecontrol setting being major methodological limitations to carrying out and drawing unbiased conclusions from such studies. Data linkage between mother and child is not possible or available in many databases currently used internationally adding to significant limitations in addressing this important association.
Strengths and Limitations
We undertook a rigorous systematic review and meta-analysis including all relevant literature to date. Reviewer selection bias was minimized by using a predefined search strategy for selection and data extraction was conducted by two independent authors.
Differences in study designs, exclusion criteria, control groups and duration of follow-up can affect the accuracy of pooled estimates for both crude and adjusted ORs. However, the findings from different case-control studies were consistent with the pooled estimates, which support our findings of an increased risk of ASD in children exposed to SSRIs during pregnancy.
As the number of studies included in the meta-analysis is limited, a funnel plot was not performed as it would not reliably identify publication bias. In addition, the studies identified for meta-analysis are relatively recent (2011-2014) with similar results; therefore we cannot exclude the possibility of publication bias. As a result, the pooled estimates may be overestimated.
Conclusion
The findings of this meta-analysis and narrative review of epidemiological studies support an increased risk of ASD in children exposed to SSRIs during pregnancy; however, causality remains to be confirmed. In view of the challenges and difficulties in evaluating this association, further replication studies in this area are recommended.
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